Key Highlights: Implications: Anupam Rasayan’s acquisition of a 48.2% controlling stake in Bliss GVS Pharma at ₹299/share completes its forward integration into finished‑dose formulations,...
Key Highlights: Implications: Sun Pharma has signed an exclusive global licensing deal (ex‑US and ex‑China) with LIB Therapeutics for lerodalcibep, a once‑monthly PCSK9 inhibitor for lower...
Key Highlights: Implications: The transaction is an internal reshuffle within Sanofi’s promoter group, so it doesn’t change overall control or the free float, and therefore has limit...
Key Highlights: Implications: Fredun Pharmaceuticals has acquired a 26% stake in Goodman Vetcare, valuing the veterinary retail company at ₹300 crore, to strengthen its footprint in ...
Key Highlights: Implications: Akums’ DCGI‑approved vonoprazan + clarithromycin + amoxicillin combikit introduces a modern, P‑CAB‑based triple therapy for H. pylori in India at a time when ...
Key Highlights: Implications: By preparing manufacturing and technology transfer now, Dr. Reddy’s can help expand long‑acting PrEP options beyond daily pills and six‑monthly injections, po...
Key Highlights: Implications: Alkem’s launch of NeuCeno (cenobamate) introduces India’s first cenobamate-based anti‑seizure medication for adults with partial‑onset seizures, adding a high...
Key Highlights: Implications: Dr. Reddy’s launch of Nivorz marks its entry into India’s biosimilar immuno‑oncology segment and adds a lower‑cost checkpoint inhibitor option across 12 appro...
Key Highlights: Implications: Gland Pharma’s move to acquire Gland Pharma USA Inc. directly from its Singapore intermediate holding company is a purely internal restructuring that removes ...
Key Highlights: Implications: ChrysCapital’s planned 20–25% stake in Linux Laboratories values the CNS‑focused branded‑generics company at roughly ₹2,400–3,000 crore, reflecting ...